Non alcoholic fatty liver disease and metabolic syndrome.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Hippokratia

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 19240815PMCID PMC2633261
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Obesity and insulin resistance].

  2009cited by this paper
• Leptin, leptin receptors and the control of body weight.

  2009cited by this paper
• A decision analysis study of the value of a liver biopsy in nonalcoholic steatohepatitis

  2008cited by this paper
• Nonalcoholic fatty liver disease and mitochondrial dysfunction.

  2008cited by this paper
• Hepatic triglyceride synthesis and nonalcoholic fatty liver disease

  2008cited by this paper
• Diagnosis and therapy of nonalcoholic steatohepatitis.

  2008cited by this paper
• Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment.

  2008cited by this paper
• Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases *

  2008cited by this paper
• Inflammation and insulin resistance

  2008cited by this paper
• Recent advances in nonalcholic fatty liver disease

  2008cited by this paper
• Non-alcoholic fatty liver disease and the metabolic syndrome: an update.

  2008cited by this paper
• The future is around the corner: Noninvasive diagnosis of progressive nonalcoholic steatohepatitis

  2008cited by this paper
• Nonalcoholic fatty liver disease: Diagnosis and relation to metabolic syndrome and approach to treatment

  2008cited by this paper
• Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases.

  2008cited by this paper
• Why a cluster is truly a cluster: insulin resistance and cardiovascular disease.

  2008cited by this paper
• The blind men 'see' the elephant-the many faces of fatty liver disease.

  2008cited by this paper
• Abdominal Ultrasound for Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD)

  2007cited by this paper
• Pathogenesis and management issues for non-alcoholic fatty liver disease.

  2007cited by this paper
• Fatty liver and the metabolic syndrome

  2007cited by this paper
• Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease.

  2007cited by this paper
• Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: Present and future

  2007cited by this paper
• Pathology of fatty liver disease

  2007cited by this paper
• Review: Insulin and endothelin: an interplay contributing to hypertension development?

  2007cited by this paper
• Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease

  2007cited by this paper
• Insulin and Endothelin: An Interplay Contributing to Hypertension Development?

  2007cited by this paper
• Metabolic syndrome and NASH.

  2007cited by this paper
• Liver fat in the metabolic syndrome.

  2007cited by this paper
• The insulin resistance syndrome: physiological considerations

  2007cited by this paper
• Adiposity and Cardiovascular Disorders: Disturbance of the Regulatory System Consisting of Humoral and Neuronal Signals

  2007cited by this paper
• The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

  2007cited by this paper
• Prevalence of vascular disease in metabolic syndrome using three proposed definitions.

  2007cited by this paper
• Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers

  2007cited by this paper
• Nonalcoholic fatty liver disease.

  2007cited by this paper
• High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH

  2007cited by this paper
• Significant correlations between severe fatty liver and risk factors for metabolic syndrome

  2007cited by this paper
• Imaging of hepatic steatosis and fatty sparing.

  2007cited by this paper
• 7. 非アルコール性脂肪肝炎 (NASH) の診断と治療

  2006cited by this paper
• Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease

  2006cited by this paper
• Diagnostic evaluation of nonalcoholic fatty liver disease.

  2006cited by this paper
• Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease

  2006cited by this paper
• The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis.

  2006cited by this paper
• Blood oxidative stress markers are unreliable markers of hepatic steatosis

  2006cited by this paper
• The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver Disease

  2006cited by this paper
• In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease

  2006cited by this paper
• Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment.

  2006cited by this paper
• Genetic influences in nonalcoholic fatty liver disease.

  2006cited by this paper
• LIVER FAILURE AND LIVER DISEASE Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis

  2006cited by this paper
• Nonalcoholic Fatty Liver Disease Presenting With an Isolated Elevated Alkaline Phosphatase

  2006cited by this paper
• Oxidant Stress and Antioxidant Status Among Patients With Nonalcoholic Fatty Liver Disease (NAFLD)

  2006cited by this paper
• The metabolic syndrome as a predictor of nonalcoholic fatty liver disease.

  2006cited by this paper
• Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it.

  2006cited by this paper
• Critical nodes in signalling pathways: insights into insulin action

  2006cited by this paper
• Long‐term follow‐up of patients with NAFLD and elevated liver enzymes

  2006cited by this paper
• Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome.

  2006cited by this paper
• Histological assessment of non‐alcoholic fatty liver disease

  2006cited by this paper
• Abnormalities of renal sodium handling in the metabolic syndrome. Results of the Olivetti Heart Study

  2006cited by this paper
• Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance.

  2006cited by this paper
• Pathophysiology of nonalcoholic steatohepatitis.

  2006cited by this paper
• Epidemiology of the Metabolic Syndrome

  2005cited by this paper
• Nonalcoholic fatty liver disease

  2005cited by this paper
• Design and validation of a histological scoring system for nonalcoholic fatty liver disease

  2005cited by this paper
• Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

  2005cited by this paper
• The prevalence of the metabolic syndrome in Greece: The MetS‐Greece Multicentre Study

  2005cited by this paper
• Hepatic steatosis is associated with an increased risk of carotid atherosclerosis.

  2005cited by this paper
• Insulin resistance: A metabolic pathway to chronic liver disease

  2005cited by this paper
• Plasma adiponectin is decreased in nonalcoholic fatty liver disease.

  2005cited by this paper
• Recent concepts in non‐alcoholic fatty liver disease

  2005cited by this paper
• Nonalcoholic fatty liver disease

  2005cited by this paper
• Hepatocyte CYP2E1 Overexpression and Steatohepatitis Lead to Impaired Hepatic Insulin Signaling*

  2005cited by this paper
• The natural history of nonalcoholic fatty liver disease: a population-based cohort study.

  2005cited by this paper
• Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.

  2005cited by this paper
• Prevalence of non‐alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults

  2005cited by this paper
• Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB

  2005cited by this paper
• The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies.

  2005cited by this paper
• Metabolic syndrome scientific statement by the American Heart Association and the National Heart, Lung, and Blood Institute.

  2005cited by this paper
• Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease

  2005cited by this paper
• Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease

  2005cited by this paper
• Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population.

  2005cited by this paper
• Definition of the metabolic syndrome: current proposals and controversies.

  2005cited by this paper
• Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.

  2005cited by this paper
• Hypoadiponectinemia Predicts the Severity of Hepatic Fibrosis and Pancreatic Beta-Cell Dysfunction in Nondiabetic Nonobese Patients with Nonalcoholic Steatohepatitis

  2005cited by this paper
• Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study

  2005cited by this paper
• Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB.

  2005cited by this paper
• Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver

  2004cited by this paper
• Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance

  2004cited by this paper
• Natural history of nonalcoholic steathepatitis: A longitudinal study of repeat liver biopsies

  2004cited by this paper
• Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver

  2004cited by this paper
• Serum markers detect the presence of liver fibrosis: a cohort study.

  2004cited by this paper
• Increasing prevalence of the metabolic syndrome among u.s. Adults.

  2004cited by this paper
• Non‐alcoholic steatohepatitis in type 2 diabetes mellitus

  2004cited by this paper
• The Metabolic Syndrome and Inflammation

  2004cited by this paper
• Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity

  2004cited by this paper
• Splanchnic lipolysis in human obesity.

  2004cited by this paper
• Systemic Levels of Lipid Peroxidation and Its Metabolic and Dietary Correlates in Patients with Nonalcoholic Steatohepatitis

  2004cited by this paper
• Beyond insulin resistance in NASH: TNF‐α or adiponectin?

  2004cited by this paper
• The Role of Ultrasound in the Diagnosis of Hepatic Steatosis in Morbidly Obese Patients

  2004cited by this paper
• Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice.

  2004cited by this paper
• Insulin and insulin resistance: impact on blood pressure and cardiovascular disease.

  2004cited by this paper
• The prevalence and etiology of elevated aminotransferase levels in the United States

  2003cited by this paper
• Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics.

  2003cited by this paper

• Suppression of nonalcoholic fatty liver disease by thymoquinone associated with inhibition of miRNA-155/ROS/p53/TIMP-1-mediated fibrosis and autophagy upregulation

  2026cites this paper
• Obesity, Metabolic Syndrome and MASLD in Children: Inflammation as the Missing Link-A Short Narrative Review.

  2026cites this paper
• Different Associations of Plasma Lipopolysaccharide and Lipopolysaccharide-Binding Protein Concentrations with the Deterioration of Energy Metabolism from Healthy Individuals to Patients with Non-Alcoholic Fatty Liver Disease.

  2026cites this paper
• Bacterial Extracellular Vesicles in the Pathogenesis and Treatment of Liver Diseases

  2026cites this paper
• Positive association between serum uric acid and metabolic dysfunction-associated steatotic liver disease: insights from a Japanese health checkup cohort

  2026cites this paper
• Development of a machine learning-based model for prediction of diabetes risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)

  2026cites this paper
• Design and Protocol of the Biobank for Metabolic Syndrome Consequences (BMSC): A Prospective Cohort Study in Northwest China

  2025cites this paper
• A Relative Measurement of Oxidative Stress in NAFLD Through Cyclic Voltammetry Method for Clinical Translation

  2025cites this paper
• Exploring the Prevalence and Risk Factors of MASLD in Patients with Newly Diagnosed Diabetes Mellitus: A Comprehensive Investigation

  2025cites this paper
• 5-Aminoimidazole-4-carboxamide-1- β ${\bf {\beta}}$ -d-ribofuranoside ameliorates lipotoxicity through enhanced reticulophagy in HepG2 cells.

  2025cites this paper
• Liver function improvement after human placental extract injections in patients with chronic liver disease: Thirty case reports

  2025cites this paper
• The Occurrence of Non-Alcoholic Fatty Liver Disease among Individuals with Diabetes Mellitus: A Comparative Study

  2025cites this paper
• Metabolic syndrome components as determinants of NAFLD progression in Bangladesh: a cross-sectional study

  2025influential citation
• Lipid Metabolism Alterations in Hereditary Inorganic Pyrophosphate Deficiency Syndromes: A Narrative Review of Insights and Controversies

  2025cites this paper
• The effect of replacing grains with quinoa on cardiometabolic risk factors and liver function in patients with non-alcoholic fatty liver: a randomized-controlled clinical trial

  2025cites this paper
• Diet and Non-Alcoholic Fatty Liver Disease (NAFLD): Advances and Management Strtegies : A Comprehensive Review

  2025influential citation
• A Comprehensive Review on the Therapeutic Effects of Salvia hispanica L. (Chia) on Metabolic Dysfunction–Associated Fatty Liver Disease: Special Focus on Pathogenesis

  2025cites this paper
• Artificial intelligence survival models for identifying relevant risk factors for incident diabetes in Azar cohort population

  2025cites this paper
• Sirtuins and Gut Microbiota: Dynamics in Health and a Journey from Metabolic Dysfunction to Hepatocellular Carcinoma

  2025cites this paper
• Frequency and risk factors of metabolic associated fatty liver disease among medical students in Egypt

  2025cites this paper
• Association between fatty liver disease and risk of microvascular complications in Type-2 diabetes mellitus: A systematic review and meta-analysis

  2025cites this paper
• Exploring the Effects of Tirzepatide on Obstructive Sleep Apnea: A Literature Review

  2025cites this paper
• HCC in MASLD and ALD: Biochemical Pathways, Epidemiology, Diagnosis, and Treatment

  2025cites this paper
• Cortisol as a factor contributing to the development of non-alcoholic fatty liver disease in severely obese patients: a single-center prospective study

  2025cites this paper
• Relationship Between Frontal QRS-T Angle and Non-Alcoholic Fatty Liver Disease (NAFLD) Fibrosis Score in Patients with Stable Angina Pectoris

  2025cites this paper
• ROS-responsive MnO2 mesoporous hydrogel to modulate liver-muscle crosstalk and mitigate NAFLD-associated sarcopenia via exosomal miR-582-5p delivery

  2025cites this paper
• Impact of walnut consumption on glycemic control and anthropometric indices: a systematic review and meta-analysis of randomized controlled trials

  2025cites this paper
• Impact of fatty liver disease on hepatic function and fibrosis progression in chronic hepatitis B patients: a narrative review

  2025cites this paper
• Identification of the differential and synergic lipotoxic patterns of oleic acid, palmitic acid, and their mixture in 3D HepG2/C3A tissue using liver‐on‐chip technology

  2025cites this paper
• Relative fat mass as a predictor of gallstones: insights from national health and nutrition examination survey data

  2025cites this paper
• Metabolites involvement in the growth and spread of liver cancer

  2025influential citation
• Quercetin and Camellia sinensis leaf extract ameliorates liver steatosis in high-fat diet fed mice via suppression of oxidative stress and inflammation

  2025cites this paper
• Obesity-Induced MASLD Is Reversed by Capsaicin via Hepatic TRPV1 Activation

  2025cites this paper
• Certain Metabolic Syndrome Component Combinations are Linked to Increased Risk of Hypogonadism in Taiwanese Men

  2025cites this paper
• Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes

  2025cites this paper
• Narrative review of metabolic syndrome and its relationships with non-alcoholic fatty liver disease, gonadal dysfunction and obstructive sleep apnea

  2025cites this paper
• Protocatechuic Acid Protects Mice Against Non-Alcoholic Fatty Liver Disease by Attenuating Oxidative Stress and Improving Lipid Profile.

  2024cites this paper
• Cymbopogon schoenanthus (L) extract ameliorates high fat diet-induced obesity and dyslipidemia via reducing expression of lipogenic and thermogenic proteins.

  2024cites this paper
• Obesity, Metabolic Syndrome, and Sugar-Sweetened Beverages (SSBs) in America: A Novel Bioethical Argument for a Radical Public Health Proposal

  2024cites this paper
• Analyses of mitochondrial metabolism in diseases: a review on 13C magnetic resonance tracers

  2024cites this paper
• Aging, ROS, and cellular senescence: a trilogy in the progression of liver fibrosis

  2024cites this paper
• Unravelling the complexities of non-alcoholic steatohepatitis: The role of metabolism, transporters, and herb-drug interactions.

  2024cites this paper
• Integrative Therapies in Metabolic Syndrome

  2024cites this paper
• Autoimmune Hepatitis and Systemic Lupus Erythematosus Overlap Syndrome: A Case Report and Literature Review

  2024cites this paper
• Liver fibrosis prediction models in a population of Latina and White women

  2024cites this paper
• VCD-induced menopause mouse model reveals reprogramming of hepatic metabolism

  2024cites this paper
• Genetic Interplay Between White Matter Hyperintensities and Alzheimer Disease: A Brain-Body Perspective

  2024cites this paper
• Global burden of metabolic dysfunction-associated steatotic liver disease attributable to high fasting plasma glucose in 204 countries and territories from 1990 to 2021

  2024cites this paper
• Diagnostic and prognostic value of triglyceride glucose index: a comprehensive evaluation of meta-analysis

  2024cites this paper
• Prevalence of metabolic dysfunction‐associated steatotic liver disease in people living with HIV and on antiretroviral treatment: A systematic review and meta‐analysis protocol

  2024cites this paper
• Knowledge, Attitudes, and Determinants of Nonalcoholic Fatty Liver Disease Among Adults in Jazan Province: A Cross-Sectional Study

  2024cites this paper
• Magnetic resonance spectroscopy as a diagnostic model for assessment of liver steatosis in metabolic dysfunction-associated steatotic liver disease in non-diabetic patients

  2024cites this paper
• Insights from exploring the interrelated dynamics of gallstone disease, non-alcoholic fatty liver disease, and kidney stone disease

  2024cites this paper
• Linking Non-alcoholic Fatty Liver Disease Severity With Metabolic Syndrome Features: An Integrative Study on Clinical and Radiological Fronts

  2024cites this paper
• Frequency of Hepatosteatosis and Relationship Between Laboratory Parameters and Hepatosteatosis in Chronic Hepatitis B Patients

  2024cites this paper
• Correlation of non-alcoholic fatty liver disease and neurodegenerative disorders

  2024cites this paper
• Elevated metabolic score for visceral fat was associated with increased prevalence of gallstones in American adults: a cross-sectional study

  2024influential citation
• Risk factors of developing nonalcoholic fatty liver disease following pancreatic resection: A systematic review and meta-analysis.

  2024cites this paper
• Liver injury in COVID-19: an insight into pathobiology and roles of risk factors

  2024cites this paper
• Electrocardiographic Abnormalities in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis.

  2024cites this paper
• Adrenarche-accompanied rise of adrenal sex steroid precursors prevents NAFLD in Young Female rats by converting into active androgens and inactivating hepatic Srebf1 signaling

  2024cites this paper
• Current Evidence and Perspectives of Cluster of Differentiation 44 in the Liver’s Physiology and Pathology

  2024cites this paper
• Enhanced Anti-Inflammatory and Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement Effects of Bacillus subtilis-Fermented Fagopyrum tataricum Gaertner

  2024cites this paper
• Carthamus tinctorius L. (Safflower) Flower Extract Attenuates Hepatic Injury and Steatosis in a Rat Model of Type 2 Diabetes Mellitus via Nrf2-Dependent Hypoglycemic, Antioxidant, and Hypolipidemic Effects

  2024cites this paper
• A Rare Presentation of Laurence-Moon-Bardet-Biedl Syndrome: Atypical Retinitis Punctata Albescens and Non-alcoholic Fatty Liver Disease

  2024cites this paper
• Genistein and sex hormone treatment alleviated hepatic fat accumulation and inflammation in orchidectomized rats with nonalcoholic steatohepatitis

  2024cites this paper
• Anthocyanin: A Potential Phytochemical Candidate for the Amelioration of Non-Alcoholic Fatty Liver Disease.

  2024cites this paper
• Biological sex differences in hepatic response to in utero dimethylbenz(a)anthracene exposure.

  2024cites this paper
• Exploring Promising Therapies for Non-Alcoholic Fatty Liver Disease: A ClinicalTrials.gov Analysis

  2024influential citation
• Impact of nonalcoholic fatty liver disease on the risk of gallbladder polyps in lean and non-obese individuals: A cohort study.

  2024cites this paper
• Atorvastatin on Treatment of Nonalcoholic Fatty Liver Disease Patients

  2024cites this paper
• Copper homeostasis and cuproptosis in health and disease

  2024cites this paper
• Causes of liver test abnormalities in newly diagnosed cancer patients and the investigation of etiological factors

  2024cites this paper
• (+)-Lipoic acid reduces mitochondrial unfolded protein response and attenuates oxidative stress and aging in an in vitro model of non-alcoholic fatty liver disease

  2024cites this paper
• The Metabolic Syndrome, a Human Disease

  2024cites this paper
• The role of gut microbiota augmentation in managing non-alcoholic fatty liver disease: an in-depth umbrella review of meta-analyses with grade assessment

  2024cites this paper
• Effect of FTY720P on lipid accumulation in HEPG2 cells

  2023cites this paper
• Associations between metabolic hyperferritinaemia, fibrosis‐promoting alleles and clinical outcomes in steatotic liver disease

  2023cites this paper
• Association between liver enzymes and metabolic syndrome: a study in Bangladeshi adults

  2023cites this paper
• Development of a novel human triculture model of non-alcoholic fatty liver disease and identification of berberine as ameliorating steatosis, oxidative stress and fibrosis

  2023cites this paper
• Female and male obese Zucker rats display differential inflammatory mediator and long non-coding RNA profiles.

  2023cites this paper
• Circulating MicroRNA-30a, Beclin1 and Their Association with Different Variables in Females with Metabolically Healthy /Unhealthy Obesity

  2023cites this paper
• Uncovering the Cardiovascular Threat: A Comprehensive Examination of Liver Fibrosis and Subclinical Atherosclerosis in Non-alcoholic Fatty Liver Disease

  2023cites this paper
• Influence of nonalcoholic fatty liver disease on inflammatory bowel disease hospitalizations in the United States

  2023cites this paper
• Ablation of dual specificity phosphatase 6 protects against non-alcoholic fatty liver disease via CYP4A and MAPK.

  2023cites this paper
• Effect of dapagliflozin against NAFLD and dyslipidemia in type 2 diabetic albino rats: possible underlying mechanisms.

  2023cites this paper
• Hepatocytic Ballooning in Non-alcoholic Steatohepatitis: Bridging the Knowledge Gap and Charting Future Avenues

  2023cites this paper
• Melatonin targets ferroptosis through bimodal alteration of redox environment and cellular pathways in NAFLD model

  2023cites this paper
• Coagulation Dysfunctions in Non-Alcoholic Fatty Liver Disease—Oxidative Stress and Inflammation Relevance

  2023cites this paper
• Unravelling the Interplay: Exploring the Influence of Previous Hepatitis B Virus, Hepatitis A Virus, and Hepatitis E Virus Infections on Non-alcoholic Fatty Liver Disease

  2023cites this paper
• Insulin resistance and cardiovascular risk factors in childhood metabolic dysfunction-associated steatotic liver disease

  2023cites this paper
• Metabolic syndrome prevalence and impact on outcomes in patients with chronic graft-versus-host disease

  2023cites this paper
• Geraniol reverses obesity by improving conversion of WAT to BAT in high fat diet induced obese rats by inhibiting HMGCoA reductase

  2023cites this paper
• Individual and combined associations of alanine aminotransferase and hemoglobin with metabolic syndrome in the elderly in Qingdao, China

  2023cites this paper
• Molecular mechanisms of alcohol's effects on the human body: A review and update

  2023cites this paper
• Galectin-12 modulates Kupffer cell polarization to alter the progression of non-alcoholic fatty liver disease.

  2023cites this paper
• Vitamin E supplementation in the treatment on nonalcoholic fatty liver disease (NAFLD): Evidence from an umbrella review of meta‐analysis on randomized controlled trials

  2023cites this paper
• The impact of gut microbiome-targeted therapy on liver enzymes in patients with nonalcoholic fatty liver disease: an umbrella meta-analysis.

  2023cites this paper
• Vitamin D improves hepatic alterations in ACE1 and ACE2 expression in experimentally induced metabolic syndrome

  2023cites this paper
• Gossypetin Prevents the Progression of Nonalcoholic Steatohepatitis by Regulating Oxidative Stress and AMP-Activated Protein Kinase

  2023influential citation